Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

Chida, T. Ishida, Y. Morioka, S. Sugahara, G. Han, C. Lam, B. Yamasaki, C. Sugahara, R. Li, M. Tanaka, Y. Liang, T. J. Tateno, C. Saito, T.
JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.

Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses

Kobayashi, C. Watanabe, Y. Oshima, M. Hirose, T. Yamasaki, M. Iwamoto, M. Iwatsuki, M. Asami, Y. Kuramochi, K. Wakae, K. Aizaki, H. Muramatsu, M. Sureau, C. Sunazuka, T. Watashi, K.
Viruses. 2022 Apr 6;14(4). pii: v14040764. doi: 10.339/v14040764.

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model

Ye, X. Tateno, C. Thi, E. P. Kakuni, M. Snead, N. M. Ishida, Y. Barnard, T. R. Sofia, M. Shimada, T. Lee, A. C. H.

ACS Infect Dis. 2018 Nov 8. doi: 10.1021/acsinfecdis.8b00192.

A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide

Kaneko, M. Watashi, K. Kamisuki, S. Matsunaga, H. Iwamoto, M. Kawai, F. Ohashi, H. Tsukuda, S. Shimura, S. Suzuki, R. Aizaki, H. Sugiyama, M. Park, S. Y. Ito, T. Ohtani, N. Sugawara, F. Tanaka, Y. Mizokami, M. Sureau, C. Wakita, T.

J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15.